Market Cap : 2.85 B | Enterprise Value : 2.8 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PTC Therapeutics has the Momentum Rank of 4.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, PTC Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Momentum Rank distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Momentum Rank falls into.
Thank you for viewing the detailed overview of PTC Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Seekingalpha 2021-01-23
By Zacks 2022-02-22
By Zacks 2020-10-29
By Zacks 2022-02-15
By Zacks 2020-08-18
By Seekingalpha 2022-02-23
By Zacks 2021-02-25
By Zacks 2020-08-27
By Seekingalpha 2021-01-20
By Zacks 2021-10-28